Targeting a protein to reduce breast cancer spread
Targeting WASF3 to suppress metastasis
['FUNDING_R01'] · UNIVERSITY OF GEORGIA · NIH-10461806
This study is exploring a new way to stop breast cancer from spreading by targeting a specific protein that helps cancer cells invade other areas, and it aims to create better treatment options for patients with metastatic breast cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF GEORGIA (nih funded) |
| Locations | 1 site (ATHENS, UNITED STATES) |
| Trial ID | NIH-10461806 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to inhibit the spread of breast cancer by targeting a specific protein called WASF3, which is crucial for cancer cell invasion and metastasis. The study utilizes stapled peptides, which are modified amino acids designed to disrupt the interactions that stabilize WASF3, thereby preventing cancer cells from spreading to other parts of the body. By focusing on this mechanism, the research aims to develop new treatment strategies that could improve outcomes for patients with metastatic breast cancer, who currently have limited options. If successful, this approach may also be applicable to other cancers that rely on WASF3 for their invasive properties.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with metastatic breast cancer who are seeking new treatment options.
Not a fit: Patients with early-stage breast cancer or those whose cancer is not driven by WASF3 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the spread of breast cancer and improve survival rates for patients.
How similar studies have performed: While targeting protein interactions is a relatively novel approach, there have been promising results in other studies using similar strategies to inhibit cancer metastasis.
Where this research is happening
ATHENS, UNITED STATES
- UNIVERSITY OF GEORGIA — ATHENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KENNEDY, EILEEN J — UNIVERSITY OF GEORGIA
- Study coordinator: KENNEDY, EILEEN J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.